A Step Toward High Throughput Epigenetics Research
Credit: Hamilton Robotics
Hamilton Robotics and Zymo Research Corporation announced an ongoing collaboration that unites Zymo Research’s epigenetics innovations with Hamilton’s high-throughput workflow expertise. A number of Zymo Research assay chemistries are now optimized for use on Hamilton’s automated liquid handling workstations, including a time-saving and robust automated method for non-biased extraction of DNA and RNA. Additional integrated workflows will be released to strengthen epigenetics research in a wide range of markets, from academia to diagnostics and more.
Epigenetics may hold important keys to unlocking a myriad of diseases and disorders, including cancer, autism, Alzheimer’s, addictions and more. According to market research from Stratistics MRC, the global epigenetics market is expected to reach $1,286M by 2022 with a CAGR of 14.4%. "The implications for understanding and regulating epigenetic mechanisms are both staggering and fascinating," commented Marc Van Eden, VP Business Development at Zymo Research. "By combining our like-minded ways of thinking and respective strengths, mutual Hamilton Robotics and Zymo Research customers can fully focus their efforts towards this powerful scientific realm without distraction."
Debbie Bowers, VP of Robotic Operations at Hamilton Robotics agreed, "Especially in diagnostics, epigenetics methods are transitioning into higher throughputs and sequencing, but this doesn’t have to be a complex project. Our collaboration allows researchers to assimilate with an optimized, robust solution, without unknowns or time-consuming delays, so they are up and running quickly."
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
For centuries, gardeners have attempted to breed blue roses with no success. But now, thanks to modern biotechnology, the elusive blue rose may finally be attainable. Researchers have found a way to express pigment-producing enzymes from bacteria in the petals of a white rose, tinting the flowers blue.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
12th Edition of International Conference on Infectious Diseases
Apr 22 - Apr 23, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019